Literature DB >> 659585

Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.

S A Fine, L A Frohman.   

Abstract

The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. To distinguish between these effects, 10 normal subjects (6 male, 4 female) and 8 patients with hyperprolactinemia associated with pituitary tumors were given l-dopa, 0.5 g alone, or 0.1 g after a 24-h pretreatment with carbidopa, 50 mg every 6 h, which produces peripheral dopa decarboxylase inhibition. Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13+/-2 ng/ml) after l-dopa alone (48+/-4%) and after l-dopa plus carbidopa (58+/-6%). In patients with pituitary tumors and elevated plasma PRL (73+/-14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47+/-6%). However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19+/-4%) which was significantly less than after l-dopa alone (P < 0.001). Urinary homovanillic acid excretion, which reflected peripheral dopa decarboxylation was similar in controls and tumor patients after l-dopa both alone and after carbidopa pretreatment. Comparable suppression of PRL levels in response to a dopamine infusion (4 mug/kg per min for 3 h) was observed in controls and tumor patients. The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. In contrast, patients with tumors, while retaining peripheral dopaminergic inhibitory effects on PRL secretion, exhibit a marked reduction of central dopaminergic inhibition of PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659585      PMCID: PMC372615          DOI: 10.1172/JCI109022

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Proceedings: The importance of intracerebral decarboxylation of L-DOPA in the suppression of prolactin secretion.

Authors:  S Franks; N F Lawton; N J Marshall
Journal:  J Physiol       Date:  1975-11       Impact factor: 5.182

2.  [Administration of hypothalamic extracts to the rat pituitary in vitro, with a view to controlling the secretion of prolactin].

Authors:  J L PASTEELS
Journal:  C R Hebd Seances Acad Sci       Date:  1962-04-02

Review 3.  The central nervous system and Cushing's syndrome.

Authors:  D T Krieger
Journal:  Mt Sinai J Med       Date:  1972 Sep-Oct

4.  Levodopa suppression of prolactin in nonpuerperal galactorrhea.

Authors:  W B Malarkey; L S Jacobs; W H Daughaday
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

5.  Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.

Authors:  V J Lotti; C C Porter
Journal:  J Pharmacol Exp Ther       Date:  1970-04       Impact factor: 4.030

6.  An assay for growth hormone and prolactin-releasing activities using a bovine pituitary cell culture system.

Authors:  L J Machlin; L S Jacobs; N Cirulis; R Kimes; R Miller
Journal:  Endocrinology       Date:  1974-11       Impact factor: 4.736

7.  Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.

Authors:  M Szabo; C Nakawatase; N Kovathana; L A Frohman
Journal:  Neuroendocrinology       Date:  1977       Impact factor: 4.914

8.  Cyproheptadine-induced remission of Cushing's disease.

Authors:  D T Krieger; L Amorosa; F Linick
Journal:  N Engl J Med       Date:  1975-10-30       Impact factor: 91.245

9.  The quantitative determination of 3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid) in urine.

Authors:  T L Sato
Journal:  J Lab Clin Med       Date:  1965-09

10.  Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.

Authors:  D L Kleinberg; G L Noel; A G Frantz
Journal:  N Engl J Med       Date:  1977-03-17       Impact factor: 91.245

View more
  20 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Reduced number of natural killer cells in patients with pathological hyperprolactinemia.

Authors:  R Gerli; P Rambotti; I Nicoletti; S Orlandi; G Migliorati; C Riccardi
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

Review 3.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

4.  Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia.

Authors:  R Gerli; C Riccardi; I Nicoletti; S Orlandi; C Cernetti; F Spinozzi; P Rambotti
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

Review 5.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

6.  Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics.

Authors:  A E Pontiroli; L Falsetti
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

7.  A possible role of endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human.

Authors:  J D Veldhuis; T J Worgul; R Monsaert; J M Hammond
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

8.  Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man.

Authors:  J I Nurnberger; S Simmons-Alling; L Kessler; S Jimerson; J Schreiber; E Hollander; C A Tamminga; N S Nadi; D S Goldstein; E S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Effects of L-dopa on plasma levels of parathyroid hormone in calves.

Authors:  J W Blum; D Schams; W Born; M Da Prada
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

10.  Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.

Authors:  A Martinez-Campos; P Giovannini; E Parati; A Novelli; T Caraceni; E E Müller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.